Key Drivers
- Strong liquidity
- Weak recent quarter
- Cash flow drop
AIAI Summary
TBPH should now be viewed as a special-situation merger spread rather than a standalone biotech, with the main investable upside coming from the Zymeworks deal closing cleanly and any CVR value from ampreloxetine, while the biggest risk is delay, litigation, or deal failure given weak standalone operating momentum.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Weak recent quarter
- •Cash flow drop
TBPH has a very strong balance sheet and low leverage, but its latest quarter showed a sharp drop in profitability and cash flow, which is the main investment risk.
Price Behavior
Key Price Behavior Insights:
- •Tight range
- •Clear support
- •Breakout needed
TBPH remains flat to mildly higher in a tight consolidation, with support around $16.81-$16.84 and resistance near $16.97-$17.01, so a clean break above $17.00 is needed to confirm upside momentum.
Repeated stalling near $17.00 shows indecision and limited follow-through
Sentiment & News
Key News Insights:
- •Sale process
- •Expense discipline
- •Cash strength
TBPH is moving toward a Zymeworks acquisition while showing improving fundamentals, with higher collaboration revenue, sharp expense cuts, strong cash/no debt, and solid TRELEGY momentum.
The deal provides clear exit visibility while recent operating improvements and balance-sheet strength support the investment case in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings